Zealand Pharma A/S (OTCMKTS:ZLDPF) Given Consensus Recommendation of "Buy" by Brokerages

Key Points

• Zealand Pharma A/S has received a consensus rating of "Buy" from seven analysts, with five analysts recommending a strong buy.
• Despite a strong consensus, the company's most recent earnings report indicated a loss, missing EPS estimates and generating revenue well below expectations.
• The stock's 1-year high is $136.76, while it has recently been trading around $61.00, reflecting a significant drop from its peak.

Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) have been assigned a consensus rating of "Buy" from the seven analysts that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, one has given a buy rating and five have issued a strong buy rating on the company.

A number of analysts have recently issued reports on the company. Zacks Research cut Zealand Pharma A/S from a "hold" rating to a "strong sell" rating in a research report on Friday, August 15th. BNP Paribas upgraded Zealand Pharma A/S to a "strong-buy" rating in a research note on Tuesday, July 1st. Wells Fargo & Company upgraded Zealand Pharma A/S to a "strong-buy" rating in a research note on Thursday, July 24th. Finally, Barclays upgraded Zealand Pharma A/S to a "strong-buy" rating in a research note on Monday, July 7th.

Zealand Pharma A/S Stock Performance

Shares of ZLDPF remained flat at $61.00 during mid-day trading on Wednesday. The stock had a trading volume of 77 shares, compared to its average volume of 490. Zealand Pharma A/S has a 52 week low of $49.98 and a 52 week high of $136.76. The stock has a market cap of $4.33 billion, a PE ratio of 4.28 and a beta of 0.71. The business's fifty day moving average price is $56.82 and its 200-day moving average price is $69.79. The company has a current ratio of 25.10, a quick ratio of 25.07 and a debt-to-equity ratio of 0.03.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last released its quarterly earnings data on Thursday, August 14th. The company reported $16.06 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $16.72 by ($0.66). Zealand Pharma A/S had a net margin of 73.90% and a return on equity of 82.30%. The business had revenue of $1.43 billion during the quarter, compared to analyst estimates of $9.18 billion. Research analysts anticipate that Zealand Pharma A/S will post -2.19 EPS for the current year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.